CBD May Inhibit the Pain Reducing Effects of THC

Wednesday, 16 January 2019

“Which is why it is important to know how cannabis acts as medicine. Don’t try to treat yourself with ditch weed, see a knowledgeable doctor. CBD acts as a NAM (negative allosteric modulator) to THC. This is sometimes beneficial (decreasespsycho active effects and allows THC to work longer) and sometimes possibly detrimental, as in this study.”
- Dr. David Hepburn

Abstract:

Humans typically self-administer cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) together repeatedly (as in cannabis, cannabis extract, or Sativex®) to relieve pain. It has been suggested that one benefit of the drug combination may be decreased tolerance development.
The decrease in THC's antinociceptive effects after repeated CBD exposure may be due to CBD-induced inhibition of THC metabolism, and/or antagonism of THC effects that emerge with repeated CBD treatment.

Read full article here:


Visit 

Dr. Dave Hepburn website: https://doctordavidhepburn.com

Medical Cannabis Laws Decreases violent crime by 20% in California

Tuesday, 15 January 2019

“Researchers found no influence of the legalisation of cannabis for medicinal purposes in the USA nonviolent property crime at the national level.”
-    Dr. David Hepburn

Abstract:

Most U.S. states have passed medical marijuana laws.
This document presents a study of the effects of these laws on violent and property crime.
It´s interesting to find that in California the medical marijuana law reduced both violent and property crime by 20%.

Read full article here:


Dr. Dave Hepburn website: https://doctordavidhepburn.com

Brianne, Alzheimers, Probiotics, and CBD

Monday, 14 January 2019

“In a remarkable paper, neurologist Ethan Russo connects receptors, epidemiology, the microbiome, neuroinflammation, and cannabis to explain possible therapeutic targets in treatments of troubling neurodegenerative conditions like Parkinson’s and Alzheimer’ Diseases. I challenge you to follow the bouncing ball. This one paper could keep the entireIvy League busy for a decade.”
- Dr. David Hepburn

Abstract:

Neurological therapeutics have been hampered by its inability to advance beyond symptomatic treatment of neurodegenerative disorders into the realm of actual palliation, arrest or reversal of the attendant pathological processes.

While cannabis-based medicines have demonstrated safety, efficacy and consistency sufficient for regulatory approval in spasticity in multiple sclerosis (MS), and in Dravet and Lennox-Gastaut Syndromes (LGS), many therapeutic challenges remain. 

The review examines the intriguing promise that recent discoveries regarding cannabis-based medicines offer to neurological therapeutics by incorporating the neutral phytocannabinoids tetrahydrocannabinol (THC), cannabidiol (CBD), their acidic precursors, tetrahydro cannabinolic acid (THCA) and cannabidiolic acid (CBDA), and cannabis terpenoids in the putative treatment of five syndromes, currently labeled recalcitrant to therapeutic success, and wherein improved pharmacological intervention is required: intractable epilepsy, brain tumors, Parkinson disease (PD), Alzheimer disease (AD) and traumatic brain injury (TBI)/chronic traumatic encephalopathy (CTE).

Read the full article here:


Dr. Dave Hepburn website: https://doctordavidhepburn.com

Cannabis Research in Tourette Syndrome

“An Israeli study showed that of the patients without syndrome who tolerated cannabis treatment, many experienced a reduction in tic severity, better sleep and improved mood.”
-     Dr. David Hepburn

Abstract:

Patients with Gilles de la Tourette syndrome (GTS) experience reduced function and impaired quality of life. The current medical treatments for this syndrome can cause significant side effects and offer partial symptomatic relief.

In a few small trials medical cannabis (MC) has been suggested to offer symptomatic relief with a relatively benign side effect profile. We conducted a real-life assessment of clinical benefit and adverse effects of chronic MC treatment among patients with GTS.

Forty-Two GTS patients (33 males, mean age 34.5) were interviewed for this study. The total global impression score of efficacy was 3.85 out of a total of 5 possible points. Patients reported during the free discussion part of the interview about a reduction in tic severity, better sleep and improved mood as positive effects of MC.

Thirty-eight patients reported any kind of benefit from treatment while 10 patients with more than one year of consumption elected to stop treatment with MC for various reasons including severe side effects as psychosis in one patient.

Read the full article here:


Dr. Dave Hepburn website: https://doctordavidhepburn.com

Why Women Don’t Forget

“Men appear to have 41% more CB1 receptors in the brain. Unfortunately for men of the male species, this is inversely related to working memory. (No memory of working). The sex difference in the ECS is becoming more interesting in explaining reactions and abilities in both.”
-    Dr. David Hepburn 

Abstract:

The endocannabinoid system (ECS) has a widespread neuron modulatory function in the central nervous system and is involved in important aspects of brain function including brain development, cortical rhythms, plasticity, reward, and stress sensitivity. 

Many of these effects are mediated via the cannabinoid CB1 receptor (CB1R) subtype. 
Animal studies convincingly have shown the interaction between the ECS and sex hormones, as well as a sex difference of higher brain CB1R in males. Human in vivo studies of sex difference has yielded discrete pant findings.

Read the full article here:


Dr. David Hepburn website: https://doctordavidhepburn.com

Related Posts Plugin for WordPress, Blogger...